Skip to main content

Transgenomic Sees Q1 Losses Narrow, Slight Dip in Revenues

NEW YORK, May 5 - Transgenomic today reported its financial results for the first quarter ended March 31, 2003.


The company posted first-quarter revenues of $9.5 million, down slightly from $9.8 million year-over-year.


Slightly lower R&D expenses of $2.3 million, compared to $2.8 million in the year-ago period, contributed to a narrowed operating loss of $3.5 million compared to $3.6 million in the first quarter of 2002.


Net loss for the quarter was $3.6 million, or $0.15 per share. This compares to a net loss of $3.4 million, or $0.14 per share, in the first quarter of 2002.


Transgenomic had $6.4 million in cash, cash equivalents, and short-term investments as of March 31, 2003, compared to $13.3 million as of December 31, 2002.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.